DA-1726 / Dong-A, MetaVia - LARVOL DELTA

DA-1726 Demonstrates Comparable Weight Loss and Distinct Metabolic Profile Compared With Retatrutide (OBESITY WEEK 2026) - No abstract available

Metabolic Disorders

'As patients in our ongoing 24-week dose-titration study continue to receive extended treatment at their highest achieved dose levels, we look forward to evaluating whether longer treatment can further enhance reductions in waist circumference, weight loss and other important cardiometabolic measures' (PRNewswire) - "'We anticipate reporting 16-week topline data in the fourth quarter of this year, followed by 24-week topline results in the first quarter of 2027'."

P1 data • Trial status • Obesity

MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction (PRNewswire) - "Data from the study showed that tissue-to-plasma ratios increased over time, indicating prolonged retention of DA-1726-derived radioactivity in tissues relative to plasma. Consistent with this finding, the greatest exposure outside of the injection site occurred in abdominal, subcutaneous and brown fat, as well as the liver....The preclinical study data also demonstrated prolonged retention of DA-1726-derived radioactivity in tissues through the final 144-hour assessment, consistent with the prolonged pharmacokinetic profile supporting once-weekly dosing of DA-1726."

Preclinical • Obesity

Anticipated Clinical Milestones (TradingView) - "Data readout from Phase 1 Part 3, 16-week titration studies, evaluating titration to 48 mg in one step and 64 mg via a two-step regimen, is expected in the fourth quarter of 2026."

P1 data • Obesity

MetaVia…announced that all enrolled active patients in Part 3 of its Phase 1 clinical trial evaluating DA-1726 for the treatment of obesity have successfully completed dose titration and are now receiving their highest target doses in both study cohorts (PRNewswire) - "The Phase 1 Part 3 trial has a planned enrollment of approximately 40 obese, otherwise healthy adult subjects, across two parts, with approximately 20 subjects per part, randomized 4:1 (16 active; 4 placebo)....Topline Data Remains on Track for Fourth Quarter 2026."

Enrollment status • P1 data • Obesity

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DA-1726, an Oxyntomodulin Analogue: Phase 1 Higher-Dose Cohort Results (ADA 2026) - P1 | "DA-1726 was generally well tolerated up to 48 mg, with mainly mild-to-moderate GI AEs and no new safety signals. Clinically meaningful, statistically significant body weight reductions at higher doses were consistent with the dose-proportional PK profile and support continued development for obesity."

Clinical • First-in-human • Late-breaking abstract • P1 data • PK/PD data • Metabolic Disorders • Obesity

Safety, tolerability, pharmacokinetics, and pharmacodynamics of DA-1726, an oxyntomodulin analogue, in a higher-dose phase 1 cohort with exploratory noninvasive liver assessment (EASL 2026) - P1 | "DA-1726 was generally well tolerated up to 48 mg, with predominantly mild-to-moderate GI AEs and no new safety signals. Clinically meaningful and statistically significant weight loss was observed. In addition, exploratory FibroScan-based assessments suggest early trends toward improvement in liver-related parameters, supporting further evaluation in longer-term studies."

Clinical • First-in-human • Late-breaking abstract • Non-invasive • P1 data • PK/PD data • Cardiovascular • Genetic Disorders • Hepatology • Metabolic Disorders • Obesity

Meta Presents Phase 1 DA-1726 Data Showing Up to 9.1% Weight Loss and Early Liver Improvements (TradingView) - "Presented late-breaking Phase 1 data at EASL 2026 for DA-1726, a dual GLP-1/GCGR oxyntomodulin analogue; 48 mg cohort achieved mean weight loss of 6.1% at Day 26 and 9.1% at Day 54 (p < 0.05 vs placebo at Day 26); Waist circumference fell 5.8 cm at Day 26 and 9.8 cm at Day 54, supporting metabolic benefit; Exploratory FibroScan showed liver improvements: CAP −20.0 dB/m vs +24.0 dB/m placebo; VCTE −10.3% vs +13.8% placebo; DA-1726 was generally well tolerated to 48 mg with no serious adverse events or treatment-related discontinuations."

Late-breaking abstract • P1 data • Obesity

MetaVia presents three abstracts on obesity and MASH pipeline at ADA 2026 (BioNews) - "Phase 1 high-dose trial of DA-1726 yields safety, tolerability, and PK/PD data - Vanoglipel + resmetirom and vanoglipel + metformin combination study targeting MASH and diabetes...Regarding vanoglipel, two separate studies will be presented at the conference. Chae Yu-na...will present findings demonstrating the synergistic hepatoprotective and weight reduction effects observed with the combination therapy of vanoglipel and resmetirom. The study was conducted using diet-induced obesity models and biopsy-confirmed MASH mouse models...In addition, Kim Tae-hyoung will present research findings on the synergistic effects of blood glucose control and weight reduction observed with the combination therapy of vanolipel and metformin. The study evaluated the combined effects of vanolipel and metformin using diet-induced obesity mouse models."

P1 data • Preclinical • Metabolic Dysfunction-Associated Steatohepatitis • Obesity

MetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026 (PRNewswire) - "'DA-1726 continues to demonstrate potential for a differentiated, best-in-class profile and is currently being evaluated in a 16-week Phase 1 Part 3 titration study designed to optimize higher dose levels and tolerability, with data expected in the fourth quarter of this year.'"

P1 data • Obesity

MetaVia…announced that the first patient has been dosed in Part 3 of its Phase 1 clinical trial evaluating DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors (PRNewswire) - "The Phase 1 Part 3 trial is expected to enroll a total of 40 obese, otherwise healthy adult subjects, across two parts, with 20 subjects per part, randomized 4:1 (16 active; 4 placebo). Part 3A is designed to evaluate a one-step titration regimen with 16 mg for 4 weeks followed by 48 mg for 12 weeks, while Part 3B will evaluate a two-step titration regimen with 16 mg for 4 weeks, 32 mg for 4 weeks, and 64 mg for 8 weeks."

Trial status • Obesity

MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control (PRNewswire) - "The approval enables initiation of Part 3 of the Phase 1 program, which consists of two 16-week titration cohorts evaluating one-step and two-step dose-escalation strategies intended to safely reach higher target doses and further optimize tolerability. The Phase 1 Part 3 trial will enroll a total of 40 obese, otherwise healthy adult subjects, across two parts, with 20 subjects per part, randomized 4:1 (16 active; 4 placebo)....Initial dosing expected to begin in April and data expected in the fourth quarter of 2026."

P1 data • Trial status • Obesity

DA-1726-1001: First in Human Study in Subjects With Obesity, But Otherwise Healthy (clinicaltrials.gov) - P1 | N=139 | Recruiting | Sponsor: NeuroBo Pharmaceuticals Inc. | N=81 ➔ 139 | Trial completion date: Mar 2026 ➔ Nov 2026 | Trial primary completion date: Jan 2026 ➔ Nov 2026

Enrollment change • First-in-human • Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041 (PRNewswire) - "MetaVia's patent portfolio, exclusively licensed from Dong-A ST Co., Ltd., provides broad protection covering the novel peptide structure of DA-1726 as well as its design as a long-acting dual-incretin therapy. Together, these protect both the core molecule and its therapeutic use in obesity, metabolic disease, and associated cardiometabolic conditions, strengthening the company's long-term development and commercialization position in one of the fastest-growing areas of medicine."

Patent • Obesity

MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile (PRNewswire) - "Strong Glycemic Response with a 12.3 mg/dL Fasted Glucose Reduction by Day 54...By Day 26, patients receiving DA-1726 achieved a statistically significant average weight reduction of 6.1% (14.6 lbs.) (p=0.003) and a statistically significant decrease in waist circumference of 5.8 cm (2.3 inches) (p=0.006). These improvements deepened through Day 54, with an average weight loss of 9.1% (21.2 lbs.) and a statistically significant 9.8 cm (3.8 inch) (p=0.022) reduction in waist circumference....'With results expected in the fourth quarter of 2026, we are well positioned to unlock further value creation as we continue advancing DA-1726 toward later-stage development.'"

P1 data • Obesity

Safety, Tolerability, and Pharmacokinetics of DA-1726, an Oxyntomodulin Analogue in a Phase 1 Study (OBESITY WEEK 2025) - P1 | "DA-1726 demonstrated a well-tolerated safety profile up to 32 mg, with mild GI AEs that compared favorably to those of existing GLP-1 therapies. This study supports the favorable safety and preliminary efficacy of DA-1726 in obesity treatment. Additional MAD cohorts are underway to further explore its maximum tolerated dose and 48 mg cohort data will be presented in addition to the 32 mg cohort."

Clinical • P1 data • PK/PD data • Cardiovascular • Genetic Disorders • Hypoglycemia • Obesity

DA-1726, An Oxyntomodulin Analogue: A Promising Therapy for Obesity and Related Metabolic Disorders (OBESITY WEEK 2025) - "In conclusion, these findings suggest that DA-1726 offers advantages including superior weight loss, increased EE, and improved lipid metabolism. These results support the potential of DA-1726 as a promising therapeutic option for the treatment of obesity and associated metabolic disorders."

Dyslipidemia • Genetic Disorders • Metabolic Disorders • Obesity

According to the preclinical results presented at the conference, when DA-1726 was administered to obese mice fed a high-fat diet, it increased basal metabolic rate more than Lilly’s obesity and diabetes drug Mounjaro. (Chosun Biz) - "Food intake was similar, but the DA-1726 group lost more weight and had higher energy expenditure."

Preclinical • Obesity

Anticipated Clinical Milestones (PRNewswire) - "DA-1726 in Obesity: Data from the 8-week 48 mg MAD cohort to explore the non-titrated maximum tolerated dose is expected by year-end 2025....Vanoglipel (DA-1241) in MASH: The Company is currently working to schedule an end-of-Phase 2 meeting with the FDA during the first half of 2026."

FDA event • P1 data • Metabolic Dysfunction-Associated Steatohepatitis • Obesity

Dong-A ST’s DA-1726 shows promising early weight loss and metabolic benefits but lags behind established GLP-1 competitors in long-term data (Chosun Biz) - "Dong-A ST said on the 5th that an obesity drug candidate it is developing with affiliate Metabia showed up to a 6.3% (6.8 kg) reduction in body weight 26 days after dosing in a phase 1 trial...Interim phase 1 results also showed positive signals. In nine adults who received a 32 mg subcutaneous injection once weekly for four weeks, average body weight decreased by 4.3% (4.0 kg), with a maximum reduction of 6.3% (6.8 kg)."

P1 data • Obesity

MetaVia…announced that two abstracts highlighting data on DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), have been accepted for poster presentations at ObesityWeek 2025 (PRNewswire)

Clinical data • Obesity

MetaVia to Present at Upcoming Investor and Industry Conferences (PRNewswire) - "September 16-17: Obesity Science & Innovation 2025 Congress. Mr. Kim will present a company overview with a focus on DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that targets both the glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity, at this conference in Boston, Massachusetts."

Clinical • Obesity

MetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient (PRNewswire) - "MetaVia...announced that it has extended to 8 weeks from 4 weeks, the 48 mg, multiple ascending dose (MAD) cohort of its Phase 1 clinical trial of DA-1726, and has administered a fifth weekly dose to the first patient....The extension is designed to further explore the non-titrated maximum tolerated dose, explore safety and other primary, secondary and exploratory endpoints over a longer treatment duration, and evaluate longer-term early efficacy. Top-line data is expected in the fourth quarter of 2025....The Phase 1 trial is a randomized, double-blind, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple ascending doses of DA-1726 in obese, otherwise healthy subjects."

P1 data • Trial status • Obesity

MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose (PRNewswire) - "MetaVia...announced dosing of the first patient in the 48 mg, multiple ascending dose (MAD) cohort of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity. Top-line data is expected in the fourth quarter of 2025."

P1 data • Trial status • Obesity

Dong-A ST develops monthly obesity injection DA-1726 with global expansion in sight (Chosun Biz) - "Dong-A ST is currently conducting global clinical trials for the obesity treatment candidate 'DA-1726' through its subsidiary Metabia, aiming for U.S. sales approval by 2030."

FDA approval • Obesity